ライフサイエンスコーパス: phosphoethanolamine

1 (beta1->4)-ManNAc backbones substituted with phosphoethanolamine.

2 lymyxin B was consistent with the absence of phosphoethanolamine.

3 ine, 8-epi-legionaminic acid, phosphate, and phosphoethanolamine.

4 gmentation that yields hexadecanaldehyde and phosphoethanolamine.

5 out 2% of the total polar lipid, of ceramide phosphoethanolamine.

6 enosyl-L-methionine-dependent methylation of phosphoethanolamine.

7 showed that Pfpmt has strong specificity for phosphoethanolamine.

8 the parasite, is subsequently converted into phosphoethanolamine.

9 ification of lipid A with aminoarabinose and phosphoethanolamine.

10 phosphocholine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.

11 -acetyl)-1-palmitoyl-2-hydroxy-sn-gly cero-3-phosphoethanolamine.

12 ace by attaching it to the headgroup of lyso-phosphoethanolamine.

13 e, GABA) and decreased that of aspartate and phosphoethanolamine.

14 tamate, gamma-aminobutyric acid, taurine and phosphoethanolamine.

15 efflux of aspartate, glutamate, taurine and phosphoethanolamine.

16 s of aspartate, glutamate, GABA, taurine and phosphoethanolamine.

17 eleases of aspartate, glutamate, taurine and phosphoethanolamine.

18 accharide with aminoarabinose (Ara4N) and/or phosphoethanolamine.

19 P lyase (S1PL) yielding (2E)-hexadecenal and phosphoethanolamine.

20 egion by addition of 4-aminoarabinose and/or phosphoethanolamine.

21 rs derived from 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phospho

22 10-30mol% DOTAP or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1-20mol% DOPE or 1,2-dioleoyl-3-tri

23 all cases), and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine/1, 2-dimyristoyl-sn-glycero-3-phosph

24 (mol/mol), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine/1, 2-dipalmitoyl-sn-glycero-3-phosph

25 tures with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1PE, POPE) or 1-palmitoyl-2

26 1-[(2)H(31)]palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1PE-d(31)) with equimolar C

27 1-[(2)H(31)]palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1PE-d(31))/SM (1:1) and the

28 r 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0-22:6PE, PDPE) and cholesterol.

29 31)]palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0-22:6PE-d(31)) or 1-[(2)H(31)]p

30 31)]palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0-22:6PE-d(31))/SM (1:1) in the

31 evels of the bisretinoids A2E and A2-glycero-phosphoethanolamine (A2-GPE).

32 Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance.

33 c proteins play an essential role in lipid A phosphoethanolamine addition and affect lipid A palmitat

34 but no palmitoylated lipid A, suggests that phosphoethanolamine addition is sufficient to confer EGT

35 racenylmethyl)-1, 2-dihexadecyl-sn-glycero-3-phosphoethanolamine (ADHP), synthesized from anthracenal

36 lutamate, GABA, glycine, taurine, glutamine, phosphoethanolamine, alanine, serine and the free fatty

37 Position 4 of Kdo is substituted by phosphoethanolamine, also present in position 6 of the b

38 was found to be extensively derivatized with phosphoethanolamine, aminoarabinose, 2-hydroxymyristate

39 and lipid A can be chemically modified with phosphoethanolamine, aminoarabinose, or glycine residues

40 izine leads to a sharp elevation of cellular phosphoethanolamine, an intermediate in the ethanolamine

41 s, derived from 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine and 1,2-distearoyl-sn-glycero-3-phos

42 he two phosphates in the lipid A region with phosphoethanolamine and 4-aminoarabinose, which has been

43 e pyridoxal-phosphate-dependent breakdown of phosphoethanolamine and 5-phosphohydroxy-L-lysine.

44 hingosine-1-phosphate (S1P) lyase to produce phosphoethanolamine and a fatty aldehyde is the final de

45 Reperfusion caused a further increase in phosphoethanolamine and arachidonic acid levels and tran

46 n the CDP-ethanolamine pathway intermediates phosphoethanolamine and CDP-ethanolamine, and an increas

47 ld-type CRP, mutant CRP bound more avidly to phosphoethanolamine and could be purified by affinity ch

48 ic insult as evidenced by its attenuation of phosphoethanolamine and free fatty acid efflux.

49 phospholipid metabolism in gliomas involving phosphoethanolamine and glycerophosphocholine.

50 5, an antibiotic-resistant strain, confirmed phosphoethanolamine and hexosamine modification of the l

51 tumors, characterized by decreased levels of phosphoethanolamine and increased levels of glycerophosp

52 urring Escherichia coli lipids, we show that phosphoethanolamine and phosphoglycerol head groups impo

53 oligosaccharide of the LOS, the presence of phosphoethanolamine and sialic acid substituents can be

54 There were fewer O-acetyl groups and more phosphoethanolamine and sialic acid substitutions on the

55 ibly degrades sphingoid base-1-phosphates to phosphoethanolamine and the corresponding fatty aldehyde

56 -phosphocholine, 1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine, and 1,2-dihexanoyl-sn-glycero-3-pho

57 ate and Atto488-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, and CGs were fluorescently labeled

58 phoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and cholesterol, have provided stro

59 of phosphatidylcholine, phosphatidylserine, phosphoethanolamine, and phosphatidylinositol between co

60 The significance of increased asparagine, phosphoethanolamine, and taurine in the asthmatic patien

61 Asparagine, phosphoethanolamine, and taurine were significantly incr

62 n of the cationic sugar 4-aminoarabinose and phosphoethanolamine, and the LpxO-catalyzed addition of

63 ted singly or in combination with palmitoyl, phosphoethanolamine, and/or aminodeoxypentose residues.

64 3-deoxy-D-manno-octulosonic acid, and PEA is phosphoethanolamine] and four, three, or two hexoses, re

65 ine (POPC):1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine approximately 6:4 POPC:cholesterol<P

66 penta-acylated lipid A with an alpha-linked phosphoethanolamine attached to C-1 of GlcN (I) in the h

67 evious reports with N. meningitidis, loss of phosphoethanolamine attached to lipid A rendered strain

68 us free and the GPI with its nonreducing end phosphoethanolamine bearing a free amino group were synt

69 Mutation of residues implicated in zinc or phosphoethanolamine binding, or catalytic activity, rest

70 % biotinylated-cap-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (biotin-cap-DOPE).

71 atalyzes not only the first N-methylation of phosphoethanolamine but also the two subsequent N-methyl

72 ins, have increased amounts of palmitate and phosphoethanolamine but no aminoarabinose addition, sugg

73 nt msbB pmrA(Con) pagP::Tn10, which contains phosphoethanolamine but no palmitoylated lipid A, sugges

74 lta mutant relies on specific methylation of phosphoethanolamine but not phosphatidylethanolamine.

75 microM) significantly inhibited effluxes of phosphoethanolamine, but had no effect on glutamate, asp

76 ntenance of physiological levels of ceramide phosphoethanolamine by CERT in vivo is required to preve

77 choline (C6PC), 1, 2-dihexanoyl-sn-glycero-3-phosphoethanolamine (C6PE), and 1, 2-dihexanoyl-sn-glyce

78 Sphingomyelin (SM) and ceramide-phosphoethanolamines (cer-PEs) are related lipids presen

79 OMVs revealed enrichment of dihydroceramide phosphoethanolamine (CerPE).

80 l phosphorus) that contained high amounts of phosphoethanolamine (compared to those of phosphocholine

81 h-, pneumococcal C-polysaccharide (PnC)-, or phosphoethanolamine-conjugated agarose columns.

82 be purified by affinity chromatography using phosphoethanolamine-conjugated Sepharose.

83 tants) to dodecylphosphocholine micelles and phosphoethanolamine-containing lipid bilayers.

84 AGXT2L1 catalyzed a similar reaction on phosphoethanolamine, converting it to ammonia, inorganic

85 instead synthesizes the SM analogue ceramide phosphoethanolamine (CPE) as the principal membrane sphi

86 Phosphoethanolamine cytidylyltransferase (ECT) catalyzes

87 CTP:phosphoethanolamine cytidylyltransferase (ET), encoded b

88 CTP:phosphoethanolamine cytidylyltransferase (Pcyt2) is the

89 irect inhibition of the cytosolic enzyme CTP:phosphoethanolamine cytidylyltransferase (PCYT2).

90 GTA resistance and polymyxin resistance with phosphoethanolamine-decorated lipid A and demonstrate th

91 serum and polymyxin B resistance as well as phosphoethanolamine decoration of lipid A were restored

92 dependent inhibition of LpxT is required for phosphoethanolamine decoration of lipid A, which is show

93 cine, glycerol, phenylalanine, tyrosine, and phosphoethanolamine; decreases in choline-containing com

94 lamine (DOPE) and 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE), along with cholesterol and D

95 The phosphoethanolamine derivatives 1b and 2b readily form e

96 The aminolipid 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE), which has been used extensiv

97 olding into mixed 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine:diC(12:0)PC liposomes resulted in a

98 The chelate, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine diethylenetriaminepentaacetic acid,

99 find that these lipids, and particularly the phosphoethanolamine dihydroceramide (PE DHC) fraction, s

100 ctions, phosphoglycerol dihydroceramides and phosphoethanolamine dihydroceramides, were prepared free

101 ds derived from 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) and 1,2-distearoyl-sn-glycero

102 lipid mixtures, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE):DMPC (7:3) and 1,2-dilauroyl-

103 two helper lipids, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-dierucoyl-sn-glycero-

104 d with two lipids, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethyla

105 c properties such as 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) are integrated into the nanoc

106 aining the fusogenic lipid 1,2-dioleoyl-sn-3-phosphoethanolamine (DOPE) in combination with DOTAP or

107 Immobilization of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) liposome-gold nano-particle (

108 (PEI)(1.8 kDa), and 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE) units (the nanocarrier is ref

109 tterionic liposome 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) were tethered on thiol monola

110 elike helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

111 al (HII) phases of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

112 yer composed of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and subsequently 1,2-dipalmit

113 line (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) bilayers at 0, 25, 50, 75, an

114 choline (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), cholesterol, and bradykinin

115 palmitoyl phosphocholine (DPPC), dipalmitoyl phosphoethanolamine (DPPE), dipalmitoyl phosphate (DPPA)

116 line (DSPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), were used to study Gb3 packi

117 oline (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) as a function of both pressur

118 gh proportion of 1,2 distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) released up to 30% of payload

119 amine (DMPE) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), in the presence of nonexchan

120 ce of either anionic lipids, cholesterol, or phosphoethanolamine eliminates membrane binding at neutr

121 have a conserved trimannosyl core bearing a phosphoethanolamine (EthN-P) moiety on the third mannose

122 ed Man on the alpha1,2-Man that receives the phosphoethanolamine (EthN-P) moiety through which GPIs b

123 estigation of the biological significance of phosphoethanolamine extensions from lipooligosaccharide,

124 n significantly reduced levels of glutamate, phosphoethanolamine, GABA and arachidonic, myristic, pal

125 sretinoid A2-GPE is detected as sn-glycero-3-phosphoethanolamine (GPE) derivatized by two all-trans-r

126 one or two glycine residues attached to the phosphoethanolamine group at the nonreducing end.

127 osphorylated lipid A (LA) with and without a phosphoethanolamine group, and both hexa- and pentaacyla

128 y strong oriented H-bonds between waters and phosphoethanolamine groups at channel interfaces.

129 5), Phosphoethanolamine groups caused a marked attenuation o

130 active antibodies exist: one is dependent on phosphoethanolamine groups in LPS, and one is not.

131 omonoesters such as beta-glycerophosphate or phosphoethanolamine had no effect.

132 The ceramide phosphoethanolamine has a fatty amide profile with only

133 a, it has now been shown that loss of the 4' phosphoethanolamine has an impact on virulence in an ani

134 :1/OH lyso-PLs bearing the phosphoserine and phosphoethanolamine head groups, presented on albumin, w

135 g by lowering the kinetic barrier imposed by phosphoethanolamine head groups.

136 oinositol) and zwitterionic (phosphocholine, phosphoethanolamine) head groups, doubly mutated V172D/S

137 lyunsaturated lipids with phosphocholine and phosphoethanolamine headgroups.

138 e demonstrating the specificity of Pfpmt for phosphoethanolamine in vivo.

139 rabinose biosynthesis also prevented lipid A phosphoethanolamine incorporation and reduced the levels

140 in that is required for the incorporation of phosphoethanolamine into lipid A and for polymyxin B res

141 hree-step methylation reaction that converts phosphoethanolamine into phosphocholine, a precursor for

142 Phosphoethanolamine is a poor substrate.

143 that in the absence of the lactosyl group, a phosphoethanolamine is added to generate a new antigenic

144 For pathogenic Neisseria, phosphoethanolamine is added to lipid A by the phosphoet

145 modification of GPI anchors with side chain phosphoethanolamine is also discussed.

146 ification of lipid A with aminoarabinose and phosphoethanolamine is responsible for PmrA-regulated po

147 e, the anionic fluorescent lipid fluorescein phosphoethanolamine is seen to rearrange, forming worm-l

148 The N-methylation of phosphoethanolamine is the committing step in choline bi

149 I anchor is a complex structure comprising a phosphoethanolamine linker, glycan core, and phospholipi

150 maintain the balance of 4-aminoarabinose and phosphoethanolamine lipid A modifications.

151 d complex formation, specific binding to the phosphoethanolamine-lipid headgroup is also required, wh

152 to attach a PEG chain to several distearoyl phosphoethanolamine lipids, thereby differing from conve

153 ate exogenous 1-acyl-2-hydroxyl-sn-glycero-3-phosphoethanolamine (lyso-PtdEtn).

154 diseases may involve a perturbation of brain phosphoethanolamine metabolism.

155 Wild-type yeast cells, which inherently lack phosphoethanolamine methylation, acquire this activity a

156 pathway involving serine decarboxylation and phosphoethanolamine methylation.

157 ylcholine via a plant-like pathway involving phosphoethanolamine methylation.

158 of phosphoethanolamine to phosphocholine by phosphoethanolamine methyltransferase (PEAMT).

159 ite Plasmodium falciparum, a multifunctional phosphoethanolamine methyltransferase (PfPMT) catalyzes

160 P. falciparum phosphoethanolamine methyltransferase (Pfpmt) is a monop

161 Phosphoethanolamine methyltransferase (PMT) catalyzes th

162 sor, and the plant-like serine decarboxylase-phosphoethanolamine methyltransferase (SDPM) pathway, wh

163 hat knock-out of the PfPMT gene encoding the phosphoethanolamine methyltransferase enzyme completely

164 phobase methylation pathway catalyzed by the phosphoethanolamine methyltransferase in Plasmodium falc

165 ity and shown that its product is an unusual phosphoethanolamine methyltransferase with no human homo

166 e identification and characterization of the phosphoethanolamine methyltransferase, Pfpmt, of P. falc

167 The monopartite phosphoethanolamine methyltransferase, Pfpmt, plays an i

168 ative pathway named the serine-decarboxylase-phosphoethanolamine-methyltransferase (SDPM) pathway usi

169 two S-adenosylmethionine (AdoMet)-dependent phosphoethanolamine methyltransferases (PMT).

170 Phosphoethanolamine methyltransferases (PMTs) catalyze t

171 lipid synthesis in nematodes and compare the phosphoethanolamine methyltransferases (PMTs) from nemat

172 ber of a large family of known and predicted phosphoethanolamine methyltransferases (PMTs) recently i

173 Phosphoethanolamine methyltransferases add three methyl

174 med that MgrR effectively silences EptB; the phosphoethanolamine modification associated with EptB is

175 eting the phosphotransferase responsible for phosphoethanolamine modification at residue serine 68 in

176 tinct from the recently identified cellulose phosphoethanolamine modification found in other species.

177 Moreover, the role that the phosphoethanolamine modification of lipid A plays in the

178 Phosphoethanolamine modification of lipid A was present

179 ough the ManNAc residues in JGS4143 LTA were phosphoethanolamine-modified, a few of these residues we

180 ogues with a glycine residue attached to the phosphoethanolamine moiety at the nonreducing end to for

181 alogues contain an aryl group linked to an O-phosphoethanolamine moiety through amide, sulfonamide, o

182 and is catalyzed by S-adenosyl-L-methionine:phosphoethanolamine N-methyltransferase (PEAMT, EC ).

183 and we measure differences among variants of phosphoethanolamine N-methyltransferase and actin-I acro

184 Parasites lacking the phosphoethanolamine N-methyltransferase enzyme, which ca

185 emical screening identified 11 inhibitors of phosphoethanolamine N-methyltransferase that block paras

186 enzyme of the plant Cho-synthesis pathway is phosphoethanolamine N-methyltransferase, which catalyzes

187 on of phosphoethanolamine (PEA) catalyzed by phosphoethanolamine N-methyltransferases (PEAMTs).

188 rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (N-Rh-DPPE) were used as fluorescent

189 rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (N-Rh-DPPE).

190 eight glycoforms, containing the addition of phosphoethanolamine, N-acetylgalactosamine, and N-acetyl

191 phocholine and 1,2-dipalmitoyl- sn-glycero-3-phosphoethanolamine- N-[methoxy(polyethylene glycol-2000

192 the exchange of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-n,n-Dimethyl-n-(2',2',6', 6'-tetrame

193 for biotin-cap-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benz oxadiazol-4-yl

194 d lipid, NBD-DOPE [1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-y l

195 tidylcholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000]

196 ne and DSPE-PEG [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polythylene glycol)].

197 ugates (i.e. , 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxypoly(e thylen e glycol)200

198 arboxamide and 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxypoly(e thylen e oxide)5000

199 We have previously shown that phosphoethanolamine on the lipid A portion of lipooligos

200 However, the in vivo substrate (phosphoethanolamine or phosphatidylethanolamine) is not

201 Cho), are synthesized by the transfer of the phosphoethanolamine or phosphocholine polar head group,

202 ipids as 1-O-alk-1'-enyl-2-acyl-sn-glycero-3-phosphoethanolamine or plasmenylethanolamine (PME) throu

203 We also show that the phosphoethanolamine (P-EtN) addition on heptose I in E.

204 In particular, it contains a phosphoethanolamine (P-Etn) instead of a free phosphate

205 ng transcriptional activator peptide-PEG1000-phosphoethanolamine (PE) (a cell-penetrating enhancer),

206 mI), scyllo-inositol (sI), glycine, taurine, phosphoethanolamine (PE) and increase in the levels of g

207 Phospholipids containing phosphoethanolamine (PE) headgroups within biological me

208 negative curvature lipids such as those with phosphoethanolamine (PE) headgroups.

209 ifferent minimum threshold concentrations of phosphoethanolamine (PE) lipids to reconstruct the membr

210 erophospholipids with phosphocholine (PC) or phosphoethanolamine (PE) substituents.

211 varying compositions of phosphocholine (PC), phosphoethanolamine (PE), cholesterol and the photo-poly

212 g lyso-phospholipid, phosphatidic acid (PA), phosphoethanolamine (PE), phosphatidylserine (PS), phosp

213 the native heptameric form at 2.3 A, and the phosphoethanolamine (PE)-bound octameric form at 2.7 A.

214 1,2-O-Bis[11-(Z)-hexadecenoyl]-sn-glycero-3-phosphoethanolamine (PE-16:1 omega 5c/16:1 omega 5c) was

215 ipid signals in the range of m/z 250-350 and phosphoethanolamines (PE) m/z 700-800 observed in negati

216 phocholine through the triple methylation of phosphoethanolamine (PEA) catalyzed by phosphoethanolami

217 Phosphoethanolamine (PEA) decoration of lipid A increase

218 Loss of phosphoethanolamine (PEA) from the lipid A of gonococcal

219 Phosphoethanolamine (PEA) residues on the second heptose

220 The gamma-chain Hep II contains two phosphoethanolamine (PEA) substitutions at C3 and C6/7.

221 se (PMT) catalyzes the triple methylation of phosphoethanolamine (pEA) to pCho.

222 sferase (PfPMT) catalyzes the methylation of phosphoethanolamine (pEA) to phosphocholine for membrane

223 PfPMT methylates phosphoethanolamine (pEA) to phosphocholine for use in m

224 Further, a mutation in lptA, the phosphoethanolamine (PEA) transferase responsible for mo

225 Lpt-3, a phosphoethanolamine (PEA) transferase, and LgtG, a gluco

226 ns heptose residues that can be decorated by phosphoethanolamine (PEA).

227 revealed three major components present in a phosphoethanolamine (PEA)0 and a PEA1 series.

228 ingly, blocking of the PCh-binding site with phosphoethanolamine (PEt) dramatically increased the bin

229 d a gene, lpt3, required for the addition of phosphoethanolamine (PEtn) at the 3 position on the beta

230 monoclonal antibody (Mab B5) that recognises phosphoethanolamine (PEtn) attached to the inner core of

231 composed primarily of the exopolysaccharide phosphoethanolamine (pEtN) cellulose.

232 ain lipopolysaccharide (LPS) modified with a phosphoethanolamine (pEtN) group at position 7 of the ou

233 f lgtG and determines whether a glucose or a phosphoethanolamine (PEtn) is added at a specific positi

234 ossess this epitope are immunotypes in which phosphoethanolamine (PEtn) is linked to the 3-position o

235 The zwitterionic lipids possess phosphoethanolamine (PEtn) linked to one or more GlcNAc

236 PS chemotypes harboring spontaneously labile phosphoethanolamine (PEtN) modifications connected throu

237 Addition of a phosphoethanolamine (pEtN) moiety to the outer 3-deoxy-D

238 ther these effects require its metabolism to phosphoethanolamine (PEtn) or PtdEtn.

239 4-amino-4-deoxy-l-arabinose (l-Ara4N) and/or phosphoethanolamine (pEtN) substituents.

240 as 4-amino-4-deoxy-l-arabinose (l-Ara4N) and phosphoethanolamine (pEtN) to Escherichia coli and Salmo

241 4-aminoarabinose (Ara4N) to the lipid A and phosphoethanolamine (pEtN) to the lipid A and core.

242 nsible for the transfer of the amino-residue phosphoethanolamine (pEtN) to the lipid A of V. cholerae

243 In this work, we identify a gene encoding a phosphoethanolamine (pEtN) transferase (Cj0256) that ser

244 er jejuni identified a gene encoding a novel phosphoethanolamine (pEtN) transferase Cj0256, renamed E

245 C. jejuni identified a gene encoding a novel phosphoethanolamine (pEtN) transferase, EptC (Cj0256), t

246 he lipid A of Helicobacter pylori contains a phosphoethanolamine (pEtN) unit directly linked to the 1

247 Etnppl catabolizes phosphoethanolamine (PEtN), a prominent headgroup precur

248 Phosphoethanolamine (pEtN)-modified lipid A species are

249 f these data allowed the identification of a phosphoethanolamine (pEtN)-modified variant of the N-gly

250 ng mice with synthetic supplement containing phosphoethanolamine (PHO-S) promoted an accentuated decr

251 i PHOSPHO1 is a dual-specific phosphocholine/phosphoethanolamine phosphatase enriched in mineralizing

252 orphism of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), using differential scanning

253 omposed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), with or without rough Escher

254 hosphocholine (POPC) or 1-palmitoyl 2-oleoyl phosphoethanolamine (POPE).

255 with amine-containing substituents, such as phosphoethanolamine, reduces the overall net negative ch

256 xEHP (Hp0021), followed by the addition of a phosphoethanolamine residue catalyzed by EptAHP (Hp0022)

257 substituents 4-amino-4-deoxy-L-arabinose and phosphoethanolamine respectively.

258 s of aspartate, glutamate, taurine, GABA and phosphoethanolamine rose during ischemia and then declin

259 addition of monosaccharides, fatty acid, and phosphoethanolamine(s) to phosphatidylinositol (PI).

260 ly mannosylated GPI structure containing one phosphoethanolamine side chain; and (iv) the mitochondri

261 and 1-alk-1-enyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine species.

262 elated pathways, such as changes in ceramide phosphoethanolamines, sphingomyelin, carnitines, tyrosin

263 olecules was phosphorylated, presumably by a phosphoethanolamine substituent.

264 However, loss of phosphoethanolamine substitution from the lipid A compon

265 respectively, and do not contain additional phosphoethanolamine substitution in their core glycan st

266 ions from lipooligosaccharide, we found that phosphoethanolamine substitutions from the heptose II gr

267 Our results support a role for lipid A phosphoethanolamine substitutions in resistance of this

268 sis and binding to S-adenosyl-methionine and phosphoethanolamine substrates.

269 mplexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups

270 t releases of aspartate, glutamate, glycine, phosphoethanolamine, taurine and GABA from the rat cereb

271 superfusate levels of aspartate, glutamate, phosphoethanolamine, taurine, gamma-aminobutyric acid (G

272 1-sulfonyl]-1,2-dihexadecanoyl-sn- glycero-3-phosphoethanolamine, that are sensitive to water content

273 They display >70% decrease in ceramide phosphoethanolamine (the sphingomyelin analog in Drosoph

274 PMTs) catalyze the three-step methylation of phosphoethanolamine to form phosphocholine, a critical s

275 ssion in E coli resulting in the addition of phosphoethanolamine to lipid A.

276 osphatidylcholine requires the conversion of phosphoethanolamine to phosphocholine by phosphoethanola

277 hree of the methylations required to convert phosphoethanolamine to phosphocholine.

278 ates that HcPMT1 catalyzes the conversion of phosphoethanolamine to phosphomonomethylethanolamine (pM

279 ipid A modification involves the addition of phosphoethanolamine to the 1 and 4' headgroup positions

280 lpt-3, that is required for the addition of phosphoethanolamine to the 3-position (PEtn-3) on the be

281 1 encodes a membrane-bound enzyme catalysing phosphoethanolamine transfer onto bacterial lipid A.

282 single zinc ion may be sufficient to support phosphoethanolamine transfer.

283 MCR-1 is a member of the phosphoethanolamine transferase enzyme family, with expr

284 e crystal structure of a full-length lipid A phosphoethanolamine transferase from Neisseria meningiti

285 sistant pathogens with chromosomally encoded phosphoethanolamine transferase genes.

286 from E. coli (EcBcsG(DeltaN)) functions as a phosphoethanolamine transferase in vitro with substrate

287 osphoethanolamine is added to lipid A by the phosphoethanolamine transferase specific for lipid A, wh

288 ghlight ArnT, a glycosyltransferase, EptA, a phosphoethanolamine transferase, and the AlmEFG triparti

289 we identified a homolog of eptA, a predicted phosphoethanolamine transferase, as critical for antimic

290 ely to be carried out by three different GPI-phosphoethanolamine transferases (GPI-PETs).

291 amine to the 1 and 4' headgroup positions by phosphoethanolamine transferases.

292 -O-hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphoethanolamine was covalently attached to the CH-Se

293 xadecanoyl-2-(9-Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine) was added.

294 iazol-4-yl)-1,2-dihexadecanoyl-sn- glycero-3-phosphoethanolamine, was found to be relatively insensit

295 fragment ions with three phosphates and one phosphoethanolamine were detected in all LOS analyzed.

296 ls of all amino acids, with the exception of phosphoethanolamine, were elevated during reperfusion.

297 in hexagonal phase 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, which further indicates that FP23 p

298 led to rapid accumulation of its substrate, phosphoethanolamine, which is itself an inhibitor of mit

299 to the variability in the human excretion of phosphoethanolamine, which is key for the interpretation

300 mixtures of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) with phosphatidylcholines (PCs) of

301 ethanolamine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, with an exchangeable form of choles